(Total Views: 375)
Posted On: 09/19/2025 3:12:29 PM
Post# of 157143
Statistical analysis of the Critically Ill Population receiving (IMV) or (ECMO) revealed that when Leronlimab was added to SOC,...
Leronlimab Decreased Mortality @ 14 days by 82% (P=.0233 N=62).
Patients who received Leronlimab were OVER 5 times more likely to be ALIVE at day 14 than those that received SOC only. Sounds familiar.
The length in hospital stay Decreased by 5.5 days in the critically ill population.
Aug 31st,2021....Leronlimab has been granted FTD by the FDA in HIV and CCR5 positive (mTNBC).
Leronlimab has been granted (EIND) status by the FDA for use in Covid-19 patients.
Then WE get this:
With the conclusion of both the CD10 and CD12 (AMAREX?) clinical trials it has become Clear that the DATA Available Do Not support the clinical benefits of Leronlimab for the treatment of COVID-19.
CLEAR as mud.
Leronlimab Decreased Mortality @ 14 days by 82% (P=.0233 N=62).
Patients who received Leronlimab were OVER 5 times more likely to be ALIVE at day 14 than those that received SOC only. Sounds familiar.
The length in hospital stay Decreased by 5.5 days in the critically ill population.
Aug 31st,2021....Leronlimab has been granted FTD by the FDA in HIV and CCR5 positive (mTNBC).
Leronlimab has been granted (EIND) status by the FDA for use in Covid-19 patients.
Then WE get this:
With the conclusion of both the CD10 and CD12 (AMAREX?) clinical trials it has become Clear that the DATA Available Do Not support the clinical benefits of Leronlimab for the treatment of COVID-19.
CLEAR as mud.
(8)
(0)
